跳至主要内容
临床试验/NCT01217606
NCT01217606已完成3 期

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Allergan0 个研究点目标入组 185 人开始时间: 2011年1月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
185
主要终点
Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test

研究概览

简要总结

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ocular hypertension or primary open-angle glaucoma in each eye
  • Requires treatment with IOP-lowering medication in both eyes

排除标准

  • Required chronic use of ocular medications during the study other than study medication
  • Use of any corticosteroids within 30 days
  • History of any traumatic eye surgeries
  • Cataract surgery in the past 6 months
  • Anticipated wearing of contact lenses during the study

研究组 & 干预措施

Triple Combination Therapy

Experimental

Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

干预措施: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) (Drug)

Combigan®

Active Comparator

Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.

干预措施: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution (Drug)

结局指标

主要结局

Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test

时间窗: Baseline, Week 12

Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed using a two-sample t-test.

次要结局

  • Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure(Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12)
  • Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)(Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Month 6, Month 9, Month 12)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验